Microba Life Sciences Limited (ASX:MAP)

Market Cap	41.41M -51.3%
Revenue (ttm)	14.90M -11.8%
Net Income	-19.75M
EPS	-0.04
Shares Out	608.96M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	202,839
Average Volume	114,409
Open	0.0690
Previous Close	0.0680
Day's Range	0.0680 - 0.0700
52-Week Range	0.0670 - 0.2300
Beta	2.15
RSI	35.51
Earnings Date	Apr 20, 2026

About Microba Life Sciences

Microba Life Sciences Limited provides microbiome testing, supplements, and analysis services in Australia, Europe, New Zealand, the United Arab Emirates, the United Kingdom, the United States, Asia, and Ireland. It operates in two segments, Testing Services and Supplements, and Research and Development. The company also develops pathology, therapeutics, and diagnostics services based on the human gut microbiome. In addition, it offers MetaPanel, a metagenomic test for pathogen detection; MetaXplore that provides a range of diagnostics solution...

• Industry: Diagnostics & Research
• Sector: Healthcare
• Founded: 2017
• Country: Australia
• Stock Exchange: Australian Securities Exchange
• Ticker Symbol: MAP

Financial Performance

In fiscal year 2025, Microba Life Sciences's revenue was 15.67 million, an increase of 29.60% compared to the previous year's 12.09 million. Losses were -14.94 million, -25.07% less than in 2024.